Renovaro
Renovaro
RENB
NASDAQ
0.60
USD
-61.29%
About
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11.
RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 162.3K |
| Three Month Average Volume | 18.3M |
| High Low | |
| Fifty-Two Week High | 5.25 USD |
| Fifty-Two Week Low | 0.42 USD |
| Fifty-Two Week High Date | 25 Jan 2024 |
| Fifty-Two Week Low Date | 01 Aug 2024 |
| Price and Volume | |
| Current Price | 0.5986 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 9.60% |
| Thirteen Week Relative Price Change | -62.46% |
| Twenty-Six Week Relative Price Change | -76.43% |
| Fifty-Two Week Relative Price Change | -84.74% |
| Year-to-Date Relative Price Change | -84.05% |
| Price Change | |
| One Day Price Change | -8.65% |
| Thirteen Week Price Change | -59.83% |
| Twenty-Six Week Price Change | -74.09% |
| Five Day Price Change | -12.56% |
| Fifty-Two Week Price Change | -80.88% |
| Year-to-Date Price Change | -81.12% |
| Month-to-Date Price Change | -18.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.73004 USD |
| Book Value Per Share (Most Recent Quarter) | 1.14311 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.12227 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.27506 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.33183 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.7053 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.0842 USD |
| Normalized (Last Fiscal Year) | -0.36088 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.7053 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.0842 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.7053 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.0842 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.02943 USD |
| Cash Per Share (Most Recent Quarter) | 0.00212 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.70328 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.18795 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.14621 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -30.15% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -0.15% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -516.19% |
| EPS Change (Trailing Twelve Months) | 45.84% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 6.8M |
| Net Debt (Last Fiscal Year) | 2.8M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 144 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 144 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -11,804,320 |
| Free Cash Flow (Trailing Twelve Months) | -10,830,700 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -28 |
| Net Interest Coverage (Trailing Twelve Months) | -24 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 10 |
| Total Debt to Equity (Most Recent Quarter) | 4 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -55.53% |
| Return on Assets (Trailing Twelve Months) | -60.56% |
| Return on Assets (5 Year) | -27.81% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -66.63% |
| Return on Equity (Trailing Twelve Months) | -75.08% |
| Return on Equity (5 Year) | -30.36% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -63.26% |
| Return on Investment (Trailing Twelve Months) | -68.21% |
| Return on Investment (5 Year) | -28.44% |